Market Research Logo

Global Biosimilar Market Trends & Opportunities: 2015 Edition

Global Biosimilar Market Trends & Opportunities: 2015 Edition

Scope of the Report

The report titled “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are profiled in the report.

Product Coverage

Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)
Humira, Enbrel, Remicade, Herceptin
Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh)

Company Coverage

Sandoz(Novartis)
Hospira
Teva
Dr. Reddy’s Lab

Executive Summary

Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conductive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provides some of the major opportunities for biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends for biosimilars market.

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually.

The report titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period 2014-18, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are profiled.


1. Executive Summary
2. Global Biosimilar Market
2.1 Overview of Biosimilar Market
Table 1 : Original And Biosimilar Medicine
2.1.1 History
2.1.2 Prescription of Biosimilars
2.1.3 Naming of Biosimilars
2.1.4 Determination of Biosimilarity
Table 2 : Original And Biosimilar Medicine
2.1.5 Differences between Biosimilar and Original Drugs
2.1.6 Manufacture of Biosimilars
Table 3: A stir tank bioreactor
2.1.7 Safety, Efficacy, Quality
2.1.8 Variability in Biosimilars
2.1.9 Regulating Biosimilars
Table 4: Biosimilars Omnitrope and Accofil
2.1.10 Approval Pathways of Biosimilars
Table A: List of Biosimilars approved by EMA
2.1.11 Market Segmentation by Therapeutic Area
3. Global Biosimilar Market: Sizing and Growth
3.1 Biosimilar Market Size: 2009-2013
Table 5: Global Biosimilar Market (2009-2013)-sales-U.S$ Billion
Table 6: Biosimilar Products Market Share (2013)
3.2 Forecasted Biosimilar market Size: 2014-2018
Table 7: Global Biosimilar Market Sales (2014-2018) in U.S$ Billion
4. Biosimilar Market Analysis: By Geography
Table 8: Global biosimilar market share by geography (2013)
4.1 Asia-Pacific
4.1.1 China
4.1.2 India
4.1.3 South Korea, Taiwan, ASEAN
4.1.4 Latin America
4.1.5 Brazil
4.1.6 Mexico
4.1.7 Argentina
4.2 Europe
Table 9: Biosimilar uptake across countries in Europe in 2013
4.3 U.S.A
5. Biosimilar Market: Product Analysis
5.1 Recombinant Glycosylated Biosimilars
5.1.1 Market Size: 2009-2013
Table 10: Biosimilar Market - Recombinant Glycosylated Products – Sales (2009-2013) - US$ Billion
5.1.2 Forecasted Market Size: 2014-2018
Table 11: Biosimilar Market - Recombinant Glycosylated Products – Sales (2014-2018) - US$ Billion
5.1.2.1 Original epoetin (EPO) products
5.1.2.2 Original follitropin product
Table 12: Biosimilar Market –Epoeitin and Follitropoin– Sales (2014-2018) - US$ Billion
5.1.2.3 Original Monoclonal antibodies
Table 13: biosimilar monoclonal antibody market-2013 to 2018-U.S$ Billion
5.1.2.4 Following are biologic MAb drugs that are expected to become off-patent from 2013 to 2018
Table B: Biosimilars of bevacizumab in development
Table C: Biosimilars of Adalimumab in development
Table D: Biosimilar of Entracept Approved for Development
Table E: Biosimilar of Trastuzumab Approved or in Development
5.2 Recombinant non-glycosylated proteins
5.2.1 Market Size: 2009-2013
Table 14: Biosimilar recombinant non-glycosylated Market (2009-2013)- Sales –U.S$ Billion
5.2.2 Forecasted Market Size :2014-2018
Table 15: Biosimilar recombinant non-glycosylated Market (2014-2018) –Sales-U.S$ Billion
5.2.2.1 Original G-CSF products:
Table 16: Biosimilar G-CSF Market (2014-2018)-Sales-U.S$ Billion
5.2.2.2 Somatotropin Products
6. Market dynamics of Biosimilar Market
6.1 Growth drivers
6.1.1 Patent expiry
Table 17: Blockbuster innovator drug market sales-2013-U.S$ Billion
Table F: Blockbuster innovator drugs scheduled patent expiries
6.1.2 Increase in Demand of Biologics
Table 18: Global biologics sales and growth: 2009-2013
Table G: Increase in sales of top six biologic drugs 2012-2013
6.1.3 Increase demand to lower the soaring health cost
Table 19: Potential Cost Savings across Biologic Classes
6.1.4 Focus On Therapeutic Research Areas (Diabetes, Cancer) including Monoclonal Antibody and Human Insulin
Table 20: Core Therapy Areas of biologics Sales-2013-U.S$ Billion
Table 21: Mortality rate of cancer patients-2012
6.1.5 Increase in expenditure on biologics globally
Table 22: Global spending on biologics: 2002-2017-U.S$ Billion
6.2 Challenges
6.2.1 Efficacy issues
6.2.2 Pharmacovigilance
6.2.3 Safety issues
6.2.4 Substitution
6.2.5 Regulatory approval
6.2.6 Barriers to competition
6.3 Market trends
6.3.1 Mergers and acquisitions
6.3.2 Penetration into U.S market
7. Competitive Landscape
Table H: Competitive landscape of key biosimilars players
Table 23: Global Biosimilar Players market share: 2013
Table I: characterization of biosimilar players on basis of investmental capabilities and developmental expertise
8. Company profiles
8.1 Sandoz-Novartis
8.1.1 Business overview
8.1.2 Financial overview
Table 24: Hospira Net Revenue: 2011-13 (US$ Million)
8.2 Hospira
8.2.1 Business overview
8.2.2 Financial overview
Table 25: Hospira Net Revenue: 2011-13 (US$ Million)
8.2.3 Business strategies
8.3 Teva
8.3.1 Business overview
8.3.2 Financial overview
Table 26: Teva’s net revenue of oncology and women health products: 2011-13 (US$ Million)
8.3.3 Business strategies
8.4 Dr. Reddy’s Laboratories
8.4.1 Business Overview
8.4.2 Financial overview
Table 27: Dr. Reddy’s Lab’s Proprietary Products Net Revenue: 2011-14 (US$ Million)
8.4.3 Business strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report